As a reminder, various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including those discussed in the Risk Factors section of our most recent quarterly report on Form 10-Q, which is on file with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.
Shares of Editas Medicine (NASDAQ: EDIT) are down 10.7% at 1:50 p.m. EST today on no apparent news other than it's a high-flying biotech that's fallen out of favor with biotech investors of late. Investors are likely still a little spooked about a change in leadership at Editas after James Mullen took over the CEO role from Cynthia Collins earlier this month.
There's been something of a game of musical chairs in the executive ranks of Editas Medicine (NASDAQ: EDIT) over the past couple of years. In this Motley Fool Live video, recorded on Feb. 10, Motley Fool contributors Keith Speights and Brian Orelli discuss what impact Editas' latest CEO change might have on the company. A biotech that you and I have both followed some of the years, Editas Medicine, just announced a change at the top on Monday of this week.